IGSF8 (immunoglobulin superfamily member 8) is a membrane protein that functions as a critical regulator of immune responses and cancer progression. Structurally, IGSF8 associates with tetraspanin-enriched microdomains and links them to the actin cytoskeleton 12. In immune cells, IGSF8 acts as an inducible receptor on dendritic cells that enhances CCL21-dependent migration while attenuating antigen-specific stimulation 3, and cooperates with alpha-actinins to regulate actin dynamics in the immune synapse for T-cell activation 4. Clinically, IGSF8 emerges as a dual-function cancer-associated protein. In solid tumors, IGSF8 is upregulated and associated with poor prognosis across multiple cancer types 5. Mechanistically, IGSF8 suppresses NK cell-mediated cytotoxicity by interacting with the NK receptor KIR3DL2 6, providing a targetable innate immune checkpoint. Conversely, in myeloid leukemia, IGSF8 maintains leukemia stem cells through FZD4-LRP6 signaling and β-catenin stabilization 7, suggesting context-dependent effects on malignancy 8. In preeclampsia, elevated IGSF8 impairs trophoblast migration and angiogenesis 9. IGSF8 shows developmental expression in neural tissue and organ epithelia 10, suggesting roles in tissue development. Anti-IGSF8 antibodies represent promising therapeutic strategies for multiple malignancies 6511.